CD3E
ENSG00000198851
Target class
Membrane receptor
Chromosome
11
Approved drugs
11
Clinical candidates (approved and in development)
22
- Approved drugs
- 11
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 22
- Chemical probe available
- No
- Target name
- CD3E
- Gene name
- CD3 epsilon subunit of T-cell receptor complex
- Gene symbol
- CD3E
- Protein name
- T-cell surface glycoprotein CD3 epsilon chain (T-cell surface antigen T3/Leu-4 epsilon chain) (CD antigen CD3e)
- CD3epsilon
- CD3-epsilon
- Gene biotype
- Protein coding
- Gene family
- CD molecules
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 38
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 103.36
- Tissue specificity (Gini)
- 0.755
- Tissue specificity (tau)
- 0.942
- KEGG gene identifiers
- hsa:916
- Protein interaction confidence
- 0.812952
- Protein interaction partners
- 62
- R-HSA-198933
- R-HSA-202424
- R-HSA-202427
- R-HSA-202430
- R-HSA-202433
- R-HSA-389948
- End position
- 118316175
- Start position
- 118304730
- Chromosome
- 11
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein .
- Endoplasmic reticulum
- Golgi apparatus
- Plasma membrane
- PubMed 10384095
- PubMed 15294938
- Tissue specificity (tau)
- 0.942314
- Expression inequality (Gini)
- 0.754643
Expression in transcripts per million
- Whole Blood
- 103.36
- Spleen
- 94.82
- Small Intestine - Terminal Ileum
- 45.8
- Lung
- 23.8
- Colon - Transverse
- 9.94
Expression in transcripts per million
- Whole Blood103.36
- Spleen94.82
- Small Intestine - Terminal Ileum45.8
- Lung23.8
- Colon - Transverse9.94
- Bladder9.87
- Fallopian Tube8.92
- Stomach8.85
- Adipose - Visceral (Omentum)8.73
- Thyroid7.89
- Vagina7.73
- Cervix - Endocervix7.63
- Prostate7.14
- Esophagus - Mucosa6.01
- Cervix - Ectocervix5.65
- Artery - Coronary4.65
- Minor Salivary Gland4.53
- Adipose - Subcutaneous4.39
- Uterus4.37
- Artery - Aorta4.14
- Breast - Mammary Tissue3.64
- Nerve - Tibial2.97
- Brain - Spinal cord (cervical c-1)2.92
- Skin - Not Sun Exposed (Suprapubic)2.89
- Liver2.7
And 29 more, listed on the interactive page.
- GO:0007166
- GO:0007169
- GO:0007172
- GO:0007186
- GO:0010628
- GO:0010629
- GO:0042102
- GO:0050852
- GO:0005886
- GO:0009897
- GO:0042101
- GO:0042105
- GO:0004888
- GO:0005515
- GO:0017124
- GO:0030674
- GO:0032395
- GO:0042802
Related records
Trials (681)
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- A Compassionate Use (CU) Program of Odronextamab
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States
- A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
- A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
- A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
- A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
- A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
- A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia
- A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
- A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
- A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
- A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Drugs (22)
- Blinatumomab T cell surface glycoprotein CD3 cross-linking agent
- Catumaxomab T cell surface glycoprotein CD3 cross-linking agent
- Elranatamab T cell surface glycoprotein CD3 binding agent
- Epcoritamab T cell surface glycoprotein CD3 binding agent
- Ertumaxomab T-cell surface glycoprotein CD3 epsilon chain cross-linking agent
- FBT-A05 T cell surface glycoprotein CD3 cross-linking agent
- Flotetuzumab T cell surface glycoprotein CD3 binding agent
- Foralumab T cell surface glycoprotein CD3 inhibitor
- Glofitamab T cell surface glycoprotein CD3 binding agent
- HOKT3 T-cell surface glycoprotein CD3 epsilon chain inhibitor
- MEDI-565 T-cell surface glycoprotein CD3 epsilon chain cross-linking agent
- Mosunetuzumab T cell surface glycoprotein CD3 binding agent
- Muromonab-CD3 T cell surface glycoprotein CD3 inhibitor
- Odronextamab T cell surface glycoprotein CD3 binding agent
- Otelixizumab T-cell surface glycoprotein CD3 epsilon chain binding agent
- Resimmune T-cell surface glycoprotein CD3 epsilon chain binding agent
- Solitomab T cell surface glycoprotein CD3 cross-linking agent
- Talquetamab T cell surface glycoprotein CD3 binding agent
- Tarlatamab T cell surface glycoprotein CD3 binding agent
- Teclistamab T cell surface glycoprotein CD3 binding agent